BioNexus Gene Lab (BGLC) Receivables - Other (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Receivables - Other data on file, last reported at $88983.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 62.25% year-over-year to $88983.0; the trailing twelve-month figure through Mar 2026 stood at $88983.0 (down 62.25% YoY), and the FY2025 full-year result was $81728.0, down 59.87% from the prior year.
• Receivables - Other advanced to $88983.0 in Q1 2026, from $81728.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.2 million in Q4 2023 to a low of -$335512.0 in Q1 2023.
• A 5-year average of $126035.9 and a median of $88983.0 in 2026 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other tumbled 112.83% in 2022 and jumped 1259.32% in 2023, its largest moves.
• Tracing BGLC's Receivables - Other over 5 years: stood at -$99755.0 in 2022, then jumped by 1259.32% to $1.2 million in 2023, then tumbled by 82.39% to $203660.0 in 2024, then slumped by 59.87% to $81728.0 in 2025, then rose by 8.88% to $88983.0 in 2026.
• Business Quant data shows BGLC's Receivables - Other at $88983.0 in Q1 2026, $81728.0 in Q4 2025, and $98903.0 in Q3 2025.